Mary Ann Liebert, Inc., The Leading Publisher in Biotechnology

NORD Compendium of Rare Diseases and Disorders
Recommend this title to your library



NORD Compendium of Rare Diseases and Disorders

The ONLY AUTHORIZED book on rare diseases and disorders from The National Organization for Rare Disorders (NORD)
View Sample Entries
ISBN-13:  978-0-913113-41-7

Order

This unique compendium provides comprehensive information on the diagnosis and management of over 1,100 rare diseases and disorders

Read Doody's Review!

This fully revised and expanded NORD Compendium of Rare Diseases and Disorders is the most comprehensive and authoritative resource of its kind. The Compendium provides a wealth of quick-reference information and data on more than 1,100 rare diseases and more than 1,100 organizations – from signs, symptoms, and etiology to support groups, researchers, and treatments.The book is an invaluable diagnostic tool for physicians in the early identification of rare diseases, for researchers on genetic disorders, for non-profit organizations, and for patients who can often go years with proper diagnosis.

While rare or “orphan” diseases are defined as those affecting fewer than 200,000 people in the United States, more than 25 million Americans are actually suffering from one of them. Due to the passage of the landmark Orphan Drug Act of 1983, together with the work of the National Organization for Rare Diseases (NORD), there is heightened awareness of and interest in these conditions among physicians, drug discovery researchers, government officials, and the health insurance industry. The FDA has approved 288 drugs and therapies to treat rare diseases, and over 1,400 products are in development and being tested for future approval since the Orphan Drug Act legislation was passed.  

912 page compendium

An essential reference for ALL Libraries: 
  Medical — physician and hospital reference and research
  Government — research, support, and funding
  Academic — research and education
  Industry — development of new drugs and therapies
  Public — patient information, advocacy, and support

 

Order